Monopar Therapeutics Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 8 - Loss Per Share

Note 8 - Loss Per Share

12 Months Ended

Dec. 31, 2025

Notes to Financial Statements

Earnings Per Share [Text Block]

Note 8 – Loss per Share

Basic and diluted net loss per common share was calculated as follows:

	*Years Ended December 31,*
(in thousands, except for net loss per common share)	*2025*			2024**

Numerator:
Net loss	$	(13,717	)	$	(15,586	)

Denominator:
Weighted-average common shares outstanding, basic and diluted		7,411			3,790

Net loss per common share, basic and diluted	$	(1.85	)	$	(4.11	)

Anti-dilutive potential common stock equivalents excluded from the calculation of net loss per share
Stock options to purchase common stock	617			429
Unvested restricted stock units	176			41

** Information pertaining to the number of shares outstanding gives retroactive effect to a 1 for 5 reverse stock split that became effective on August 12, 2024.